New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
New England Journal Of Medicine Publishes Results Of Global, Multicenter Enrgy Study Evaluating Zenocutuzumab-Zbco (BIZENGRI®) In NRG1+ Cancer
Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
AI tool helps find life-saving medicine for rare disease
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
The New England Journal of Medicine7d
Case 4-2025: A 41-Year-Old Man with Syncope, Ankle Swelling, and Abnormal Chest Imaging
A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...
New research could help reduce heart attack risk for people with diabetes
The blood pressure study could help doctors treating people with diabetes to reduce the risk of "major cardiovascular events" ...
Health Rounds: New type of blood thinner significantly reduces bleeding risk in trial
Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...
Study finds three new safe, effective ways to treat drug-resistant tuberculosis
Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of ...
Heart attack risk update for people with diabetes in new study on blood pressure
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...